Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1995-06-06
1998-03-03
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
A61K 9127
Patent
active
057231478
ABSTRACT:
Disclosed are multivesicular liposomes containing biologically active substances, the multivesicular liposomes having defined size distribution, adjustable average size, adjustable internal chamber size and number, and a modulated rate of the biologically active substance in contrast to the previous art. The process comprises dissolving a lipid component in volatile organic solvents, adding an immiscible aqueous component containing at least one biologically active substance to be encapsulated, and adding to either or both the organic solvents and the lipid component, a hydrochloride effective to control the release rate of the biologically active substance from the multivesicular liposome, making a water-in-oil emulsion from the two components, immersing the emulsion into a second aqueous component, dividing the emulsion into small solvent spherules which contain even smaller aqueous chambers, and then removing the solvents to give an aqueous suspension of multivesicular liposomes encapsulating biologically active substances.
REFERENCES:
patent: 4078052 (1978-03-01), Papahadjopoulos
patent: 4089801 (1978-05-01), Schneider
patent: 4145410 (1979-05-01), Sears
patent: 4224179 (1980-09-01), Schneider
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4310506 (1982-01-01), Baldeschwieler et al.
patent: 4394372 (1983-07-01), Taylor
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4588578 (1986-05-01), Fountain et al.
patent: 4599227 (1986-07-01), Dees et al.
patent: 4610868 (1986-09-01), Fountain et al.
patent: 4752425 (1988-07-01), Martin et al.
patent: 4769250 (1988-09-01), Frossen
patent: 4781871 (1988-11-01), West, III et al.
patent: 4814270 (1989-03-01), Piran
patent: 4920016 (1990-04-01), Allen et al.
patent: 5000959 (1991-03-01), Iga et al.
patent: 5021200 (1991-06-01), Vanlerberghe et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5204112 (1993-04-01), Hope et al.
patent: 5211955 (1993-05-01), Legros et al.
patent: 5334381 (1994-08-01), Unger
patent: 5334391 (1994-08-01), Clark et al.
Srommelin, International J. Pharmaceutics, 16, p. 73, 1989.
Spector et al., "Topology of Multivascular Liposomes, a Model Biliquid Foam", Langmuir 12:4704-4708, (1996).
Huang, biochemistry, 8:334-352 1969, "Studies on Phosphatidylcholine Vesicles formation and Physical charateristics".
Bang, M. Mol. Bio., 13-238-252, 1965, "Diffusion of univalent ions across the lamellae of swollen phospolipids".
Szoka,et al., Ann. Rev. Biophys. Bioeng., 9:465-508, 1980 "Comparative properties and methods of preparation of lipid vesicles (liposomes)".
Shakiba, et al., Investigative ophthalmology and visual Science, 34(10):2903-10, 1993 Sep., "Evaluation of retinal toxicity and liposome encapsulation of the Anti-CMV Drug 2'-nor-cyclic GMP".
Frucht-Perry, et al., Cornea, 11(5):393-7, 1992 Sep., "Fibrin-emeshed tobramycin liposomes: single application topical therapy of pseudomonas . . . ".
Assil, et al., Investigative Opthalomolgy and Visual Science, 32(13):3216-20, 1991 Dec., "Tobramycin liposomes. Single subconjunctival therapy of . . . ".
Assil, et al., Investigative Opthalmology and Visual Science, 32(11):2891-7, 1991 Oct., Liposome suppression of proliferative vitroeretinopathy. Rabbit . . .
Turski, et al., Magnetic Resonance in Medicine, 7(2):184-96, 1988 Jun., "Magnetic resonance imaging of rabbit brain after intracarotoid injection . . . ".
Skuta, et al., American Journal of Ophthalmology, 103(5):714-16, 1987, May 15, "Filtering surgery in owl monkeys treated with the antimetabolite . . . ".
Assil, et al., Archives of Ophthalmology, 105(3):400-3, 1987 mar, "Multivascular liposomes. Saturated release of the antimetabolite . . . ".
Barbet, et al., Biochimica et Biophysica Acta, 772(3):347-56, 1984, May 30, "Weat acid-induced release of liposome-encapsulated carboxyfluorescein".
Kim, et al., Biochim. Biophys. Acta, 646:1, 1981, "Preparation or cell-size unilamellar liposomes with high captured volume and deficed size . . . ".
Kim, et al., Biochim. Biophys. Acta, 728:339-348, 1983, "Preparation of multivesicular liposomes".
Kim, et al., Biochim. Biophys. Acta, 793:801, 1985 "Preparation of multilamellar vesicles of deficed size-distribution by solvent-spherule . . . ".
Kim, et al., Cancer Treat. Rep., 71:705-711, 1987, "Multivesicular liposomes containing cyarabine entrapped in the presence of . . . ".
Kim, et al., Cancer Research, 47:3935-3937, 1987, "Multivesicular Liposomes Containing cytosine arabinoside for slow-release intrathecal therapy".
Kim, et al., Cancer Treat Rep., 71:447-450, 1987, "Multivesicular liposomes containing cytosine arabinoside for slow-release . . . ".
Kim, et al., Cancer Chemother Pharmacology, 19:307-310, 1987, "Modulation of the peritoneal clearance of liposomal ara-C by blank liposomes".
Roy, et al., Cancer Chemother. Pharm., 28:105-108, 1991, "Multivesicular liposomes contining bleomycin for subcutaneous administration".
Kim, et al., Reg. cancer Treat., 2:170-173, 1989, "Intratumoral chemotherapy with multivescular liposomes containing 1-bD-arabino . . . ".
Kim, et al., J. Inf. Dis., 162:750-752, 1990, "Multivesicular liposomes for CSF delivery of retroviral agent DDC".
Chamberlain, et al., Archives of Neurol. 50(3):261-264, 1993, "Treatment of leptomengingeal metastasis with intraventricular administration of . . .".
Chatelut, et al., Cancer Them. Pharmacol., 32:179-182, 1993, "A slow-release methotrexate formulation for inrathecal chemotherapy".
Russack, et al., Ann. Neurol., 34:108-112, 1993, "Quantitive cerebrospinal fluid cytology in patients receiving intracavitary chemothrapy".
Kim, et al., J. Clin. Oncol., 11:2186-2193, 1993, "Extended cerebrospinal-fluid cytarabine exposure following intrathecal administration of DTC 101".
Kim, Drugs, 46:618-638, 1993, "Liposomes as carriers of cancer chemotherapy: a review".
Kim, Kim, Kim, Cancer Chemother. Pharmacol., 33:157-190, 1993, "Extended-release formulation of morphine for subcutaneous administration".
Ishii, Liposome Technology, 1:111-121, 1993, "Production and Size Control of large unilamellar liposomes by emulsification".
Cullis, et al., Phospholipids and Cellular Regulation, 1:65-123, 1985, "Structural properties and functional roles of phospholipids in . . . ".
Bonetti, et al., Cancer Chemotherapy and Pharmacology, In Press, 1993, "An extended-release formulation of methotrexate for subcutaneous . . . ".
Kim, et al., Cancer Res., 53:1596-1598, 1993, "Prolongation of drug action in CSF by encapsulation into multivesicular liposomes".
Howell Stephen B.
Kim Sinil
DepoTech Corporation
Kishore Gollamudi S.
LandOfFree
Multivesicular liposomes having a biologically active substance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivesicular liposomes having a biologically active substance , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivesicular liposomes having a biologically active substance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2245670